Solutions For RealSolutions For Real
  • Home
  • News
  • Personal Finance
    • Savings
    • Banking
    • Mortgage
    • Retirement
    • Taxes
    • Wealth
  • Make Money
  • Budgeting
  • Burrow
  • Investing
  • Credit Cards
  • Loans

Subscribe to Updates

Get the latest finance news and updates directly to your inbox.

Top News

How I Went From Side Hustle to 7 Figures Using These 4 AI Tools (No Tech Skills Needed)

July 12, 2025

How Mastering Your Nervous System Boosts Leadership Presence and Performance

July 12, 2025

Mortgage rates tick higher for first time in weeks

July 11, 2025
Facebook Twitter Instagram
Trending
  • How I Went From Side Hustle to 7 Figures Using These 4 AI Tools (No Tech Skills Needed)
  • How Mastering Your Nervous System Boosts Leadership Presence and Performance
  • Mortgage rates tick higher for first time in weeks
  • Social Security & The Big Beautiful Bill
  • Ford Recalls 850,000 Vehicles: What It Means for Your Safety and Your Finances
  • Mark Cuban Says AI Will Mint a Trillionaire. Start Your Climb Here
  • Here’s How Much Google Pays Software Engineers, Designers
  • This Former NFL Player Built a Brand Around Nasal Breathing
Saturday, July 12
Facebook Twitter Instagram
Solutions For RealSolutions For Real
Subscribe For Alerts
  • Home
  • News
  • Personal Finance
    • Savings
    • Banking
    • Mortgage
    • Retirement
    • Taxes
    • Wealth
  • Make Money
  • Budgeting
  • Burrow
  • Investing
  • Credit Cards
  • Loans
Solutions For RealSolutions For Real
Home » Eli Lilly raises full-year guidance as drug pipeline drives second-quarter profit up 85%
News

Eli Lilly raises full-year guidance as drug pipeline drives second-quarter profit up 85%

News RoomBy News RoomAugust 8, 20230 Views0
Facebook Twitter Pinterest LinkedIn WhatsApp Reddit Email Tumblr Telegram

Eli Lilly on Tuesday raised its full-year guidance as second-quarter profit jumped 85% from the same period a year ago on strong sales from the pharmaceutical giant’s drug pipeline.

The company now expects full-year revenue of between $33.4 billion to $33.9 billion, up from a previous forecast of $31.2 billion to $31.7 billion. Eli Lilly also increased its adjusted earnings guidance to a range of $9.70 to $9.90 per share for the year, up from a range of $8.65 to $8.85.

Shares of Eli Lilly jumped 10% in premarket trading Tuesday.

Here’s how Eli Lilly performed, compared with Wall Street expectations, based on a survey of analysts by Refinitiv:

  • Adjusted earnings: $2.11 per share, vs. $1.98 per share expected
  • Revenue: $8.31 billion, vs. $7.58 billion expected

The company booked net income of $1.76 billion, or $1.95 per share, for the quarter. That’s up from net income of $952.5 million, or $1.05 per share, for the same period a year ago. 

Accounting for charges associated with some intangible assets and losses on securities, the company recorded adjusted income of $1.9 billion, or $2.11 per share.

The company’s $8.31 billion in sales for the quarter marked a 28% increase from the same period a year ago. 

That revenue growth was driven by sales of breast cancer pill Verzenio, which rose 57% to $926.8 million for the quarter.

Newer drugs like Mounjaro, the company’s Type 2 diabetes injection, also fueled revenue growth, posting $979.7 million in sales for the quarter. The drug was first approved in the U.S. in May 2022 and notched just $16 million in sales in the year-ago period. 

Eli Lilly said it “has experienced and continues to expect intermittent delays fulfilling orders of certain Mounjaro doses given significant demand.”

Eli Lilly also sold the rights to its emergency diabetes treatment Baqsimi to Amphastar Pharmaceuticals in April, which brought in $579 million to the topline.

Eli Lilly’s stock has been on a tear in recent months, driven in part by positive trial results for its Alzheimer’s drug, donanemab, and the company’s progress with its promising obesity drug pipeline. 

Shares of Eli Lilly are up more than 24% for the year. With a market value of roughly $431 billion, Eli Lilly is the second-largest pharmaceutical company based in the U.S. after Johnson & Johnson.

Eli Lilly will hold a conference call with investors at 9:00 am ET. 

Executives will likely share updates on the company’s upcoming pipeline launches and recent acquisitions. That includes Eli Lilly’s $1.93 billion acquisition of Versanis, a privately held obesity drug maker. 

Executives are also likely to be asked about a lawsuit filed Monday by Nektar Therapeutics accusing Eli Lilly of undermining a drug development deal established between the two companies in 2017.

This story is developing. Please check back for updates.

Read the full article here

Share. Facebook Twitter Pinterest LinkedIn Tumblr Email

Related Articles

Lucid shares tumble following public offering of nearly 262.5 million shares

News October 17, 2024

Harris distances herself from Biden, bashes Trump in tense Fox News interview

News October 17, 2024

Alibaba’s international arm says its new AI translation tool beats Google and ChatGPT

News October 16, 2024

I bought a $54,000 abandoned house in Japan and turned it into a luxury Airbnb—take a look inside

News October 16, 2024

Trump’s crypto coin goes on sale with Election Day just three weeks out

News October 15, 2024

Cramer’s Lightning Round: Uranium Energy is ‘the real deal’

News October 15, 2024
Add A Comment

Leave A Reply Cancel Reply

Demo
Top News

How Mastering Your Nervous System Boosts Leadership Presence and Performance

July 12, 20250 Views

Mortgage rates tick higher for first time in weeks

July 11, 20250 Views

Social Security & The Big Beautiful Bill

July 11, 20250 Views

Ford Recalls 850,000 Vehicles: What It Means for Your Safety and Your Finances

July 11, 20250 Views
Don't Miss

Mark Cuban Says AI Will Mint a Trillionaire. Start Your Climb Here

By News RoomJuly 11, 2025

Kathy Hutchins / Shutterstock.comMark Cuban is making a bold prediction that has everyone talking: AI…

Here’s How Much Google Pays Software Engineers, Designers

July 11, 2025

This Former NFL Player Built a Brand Around Nasal Breathing

July 11, 2025

What My First Failed Startup Taught Me — and How I Finally Got It Right 20 Years Later

July 11, 2025
About Us
About Us

Your number 1 source for the latest finance, making money, saving money and budgeting. follow us now to get the news that matters to you.

We're accepting new partnerships right now.

Email Us: [email protected]

Our Picks

How I Went From Side Hustle to 7 Figures Using These 4 AI Tools (No Tech Skills Needed)

July 12, 2025

How Mastering Your Nervous System Boosts Leadership Presence and Performance

July 12, 2025

Mortgage rates tick higher for first time in weeks

July 11, 2025
Most Popular

51 Reasons I Won’t Lend Money to Friends and Family

August 6, 20231 Views

How I Went From Side Hustle to 7 Figures Using These 4 AI Tools (No Tech Skills Needed)

July 12, 20250 Views

How Mastering Your Nervous System Boosts Leadership Presence and Performance

July 12, 20250 Views
Facebook Twitter Instagram Pinterest Dribbble
  • Privacy Policy
  • Terms of use
  • Press Release
  • Advertise
  • Contact
© 2025 Solutions For Real. All Rights Reserved.

Type above and press Enter to search. Press Esc to cancel.